Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

109.30 -0.79 (-0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,413,854
Open 109.82
Bid (Size) 109.10 (8)
Ask (Size) 110.80 (2)
Prev. Close 110.09
Today's Range 109.04 - 111.04
52wk Range 62.69 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
Exposures COVID-19
Why Gilead Scinces Stock Tumbled on Tuesday
Via The Motley Fool
Exposures Product Safety

Performance

YTD
+19.0%
+19.0%
1 Month
+5.3%
+5.3%
3 Month
-4.1%
-4.1%
6 Month
+18.3%
+18.3%
1 Year
+68.4%
+68.4%

More News

Read More
Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes
Via Stocktwits
Exposures Product Safety
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence
Via Stocktwits
Exposures Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Reasons to Like GILD (and 1 Not So Much)
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Via Benzinga
Exposures Product Safety
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating
Via Stocktwits
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Via Stocktwits
Topics Government
Exposures Political Product Safety
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A Potentially Undervalued Biopharmaceutical Stock
Via Chartmill
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
What Analysts Are Saying About Gilead Sciences Stock
Via Benzinga
What's going on in today's session: S&P500 movers
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
From Gilead Sciences, Inc.
Via Business Wire
Is the Market Bullish or Bearish on Gilead Sciences?
Via Benzinga
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Top S&P500 movers in Monday's pre-market session
Via Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
Via Benzinga
Topics Economy World Trade
Exposures Interest Rates Tariff

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 109.30
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 06/11/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 137.04B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 137B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.